Abeona Therapeutics and REGENXBIO Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector
05 nov. 2018 07h00 HE
|
Abeona Therapeutics Inc.
Abeona granted new licenses to NAV AAV9 for the development and commercialization of treatments for MPS IIIA, MPS IIIB, CLN1 and CLN3 Batten Disease Abeona to pay REGENXBIO $20 million upfront, $10...
Abeona Announces Participation at Upcoming Conferences
28 sept. 2018 08h45 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Sept. 28, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
Abeona Announces Participation at Upcoming Conferences
04 sept. 2018 08h45 HE
|
Abeona Therapeutics Inc.
Citi's 13th Annual Biotech Conference - September 5-6th in Boston, MAJefferies Gene Therapy Summit - September 27th in New York, NY NEW YORK and CLEVELAND, Sept. 04, 2018 (GLOBE NEWSWIRE)...
Abeona Therapeutics Reports Second Quarter 2018 Financial Results and Business Highlights
09 août 2018 16h20 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
Abeona Therapeutics Announces Leadership Appointments with Max Colao as Chief Commercial Officer
26 juil. 2018 08h30 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, July 26, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
Abeona Therapeutics Announces Opening of Commercial Gene & Cell Therapy Manufacturing Facility in Ohio
31 mai 2018 08h45 HE
|
Abeona Therapeutics Inc.
-- The Elisa Linton Center for Rare Disease Therapies to support development of advanced gene and cell therapies for treatment of serious rare diseases -- Ribbon-cutting ceremony of gene and cell...
Abeona Therapeutics Provides Clinical Update on MPS IIIA Gene Therapy Trial at the 21st Annual ASGCT Meeting
18 mai 2018 09h25 HE
|
Abeona Therapeutics Inc.
ABO-102 18-month efficacy and safety data continue to demonstrate time- and dose-dependent reductions in underlying disease pathology, including decreased CSF and urine GAGs and improved liver...
Abeona Reports Update from EB-101 Gene Therapy in Epidermolysis Bullosa at 21st Annual ASGCT Meeting
17 mai 2018 09h20 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, May 17, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
Abeona Therapeutics Announces Appointment of Stefano Buono and Richard Van Duyne to its Board of Directors
14 mai 2018 08h15 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, May 14, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
Abeona Therapeutics Reports First Quarter 2018 Financial Results and Business Highlights
11 mai 2018 08h15 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, May 11, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...